Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Taylor Kohls

Physician Assistant Centerville, OH Physician Assistant

NPI 1851060024 CMS profile 10620671

1975 Miamisburg Centerville Rd, Centerville, OH 45459

Open in the dashboard

General payments

$15,960

793 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taylor Kohls of Centerville, OH is reported in the CMS Open Payments database as having received $15,960 across 793 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,515 212
2024 General $3,841 166
2023 General $3,937 205
2022 General $2,943 174
2021 General $724 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taylor Kohls
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Taylor Kohls were reported at $4,515. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Taylor Kohls Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $724 $132 $37–$438 $132
2022 $2,943 $155 $48–$522 $149
2023 $3,937 $167 $52–$557 $160
2024 $3,841 $178 $55–$600 $164
2025 $4,515 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,999 99 payments
  2. US WorldMeds, LLC $1,290 37 payments
  3. UCB, Inc. $1,028 64 payments
  4. Lilly USA, LLC $960 54 payments
  5. SK Life Science, Inc. $869 35 payments
  6. Pfizer Inc. $842 56 payments
  7. EMD Serono, Inc. $716 18 payments
  8. Neurocrine Biosciences, Inc. $673 38 payments
  9. Amneal Pharmaceuticals LLC $623 38 payments
  10. Novartis Pharmaceuticals Corporation $600 36 payments
  11. Other $6,360 318 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,438 783 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $268 2 payments
  3. Education $253 8 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $946 47 payments
  2. Gocovri $684 14 payments
  3. BOTOX $674 35 payments
  4. INGREZZA $673 38 payments
  5. Briviact $658 45 payments
  6. NURTEC ODT $655 44 payments
  7. UBRELVY $632 32 payments
  8. EMGALITY $497 37 payments
  9. KESIMPTA $458 30 payments
  10. NUPLAZID $456 27 payments
  11. Other $10,203 527 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

3,192

Median for Physician Assistant: 241

Drug cost

$440,960

Median for Physician Assistant: $4,110

Branded share of claims

19%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 13 $72,818
Nurtec Odt Rimegepant Sulfate Brand 54 $64,998
Ubrelvy Ubrogepant Brand 39 $58,712
Emgality Pen Galcanezumab-Gnlm Brand 53 $50,297
Aimovig Autoinjector Erenumab-Aooe Brand 56 $40,877
Qulipta Atogepant Brand 31 $32,480
Ajovy Autoinjector Fremanezumab-Vfrm Brand 27 $24,626
Nuedexta Dextromethorphan Hbr/Quinidine Brand 14 $21,157
Memantine Hcl Generic 314 $13,498
Lacosamide Generic 51 $9,569

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$30,078

Medicare's payments for the services billed

Medicare patients

273

Average age 75

Services billed

467

162 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 42%
Ischemic heart disease 35%
Diabetes 34%
Alzheimer's or dementia 30%
Chronic kidney disease 26%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
$665 — —
QULIPTA
$195 31 —
UBRELVY
$190 39 —
BOTOX
$184 — —
ULTOMIRIS
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

793 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record